natgillin/translations-raw huggingface dataset:
The decreases in white blood cell (WBC) and neutrophil counts occurred mainly during the first six weeks of therapy, with values remaining relatively stable thereafter. 
Do zmanjšanja koncentracij belih krvničk (WBC - white blood cell) in nevtrofilcev je prišlo predvsem v prvih šestih tednih zdravljenja, zatem pa so vrednosti ostale relativno stabilne.
Mean absolute bioavailability for imatinib is 98%. 
Absorpcija Povprečna absolutna biološka uporabnost imatiniba je 98 %.
If you are allergic to peanut or soya, do not use this medicinal product. 
Če ste alergični na sojo ali arašide, ne jemljite tega zdravila.
In patients treated with metoprolol clinical monitoring should be considered. 
Pri bolnikih, ki se zdravijo z metoprololom, je treba razmisliti o kliničnem spremljanju.
While you are taking Imatinib Actavis, your doctor will regularly check whether the medicine is working. 
Med jemanjem zdravila Imatinib Actavis bo zdravnik redno spremljal, ali zdravilo deluje.
The safety and efficacy of imatinib in children with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials. 
Varnost in učinkovitost imatiniba pri otrocih, ki imajo MDS/MPD, DFSP ali HES/CEL in so stari manj kot 18 let, nista bili dokazani v kliničnih preskušanjih.
Studies in two breast-feeding women revealed that both imatinib and its active metabolite can be distributed into human milk. 
Študije pri dveh doječih materah sta pokazali, da se tako imatinib kot njegov aktivni presnovek pri človeku lahko izločata v materino mleko.
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin instead of coumarin derivatives such as warfarin. 
Zaradi znanega povečanega tveganja za krvavitve v povezavi z uporabo imatiniba (na primer hemoragija) naj bolniki, pri katerih je potrebna antikoagulantna terapija, dobivajo nizkomolekularni ali standardni heparin namesto kumarinskih derivatov, kot je varfarin.
Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1% of CML patients. 
Zaradi jetrnih laboratorijskih nenormalnosti so zdravljenje trajno prekinili pri manj kot 1 % bolnikov s KML.
- if you are allergic to imatinib or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na imatinib ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Patients should be instructed to use measures such as protective clothing and sunscreen with high sun protection factor (SPF). 
Bolnikom je treba naročiti, naj se poslužujejo ukrepov, kot so zaščita z oblačili in uporaba zaščitne kreme z visokim zaščitnim faktorjem
Patients, who are allergic to peanut or soya, may not use this medicinal product. 
Bolniki, ki so alergični na arašide ali sojo, ne smejo jemati tega zdravila.
20 out of the 50 (40%) patients in cohort 5 received haematopoietic stem cell transplant. 
20 od 50 bolnikom (40 %) v 5. kohorti so presadili krvotvorne matične celice.
Ask your pharmacist how to throw away medicines you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več se posvetujte s farmacevtom.
Blast crisis is defined as blasts ≥ 30% in blood or bone marrow or extramedullary disease other than hepatosplenomegaly. 
Blastno krizo opredeljuje ≥ 30 % blastov v krvi ali kostnem mozgu ali ekstramedularna bolezen, ki ni hepatosplenomegalija.
Complete (Confirmed3) [95% CI] Partial 
Popoln (potrjen3) [95 %interval zaupanja]
Hands should be washed immediately after handling open capsules. 
Takoj po rokovanju z odprtimi kapsulami si je treba umiti roke.
The complete molecular response rate was 48% (49 out of 102 evaluable patients). 
Delež bolnikov s popolnim molekularnim odzivom je bil 48 % (49 od 102 za oceno primernih bolnikov).
Study AUS01 
Študija AUS01
As expected on the basis of the study design, no difference was observed in remission duration, disease-free survival or overall survival, although patients with complete molecular response and remaining in minimal residual disease had a better outcome in terms of both remission duration (p=0.01) and disease-free survival (p=0.02). 
Kot je bilo pričakovati glede na načrt študije, ni bilo nobene razlike v trajanju remisij, preživetju brez bolezni ali preživetju nasploh, čeprav so imeli bolniki s popolnim molekularnim odzivom in tisti z minimalno rezidualno boleznijo boljši izid glede trajanja remisije (p=0,01) in preživetja brez bolezni (p=0,02).
However, since the effects of low-dose exposure of the infant to imatinib are unknown, women taking imatinib should not breast-feed. 
Vendar učinki izpostavljenosti dojenčka majhnim odmerkom imatiniba niso znani, zato ženske, ki jemljejo imatinib ne smejo dojiti.
- Do not take a double dose to make up a forgotten dose. 
- Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
- Recurrence (reactivation) of Hepatitis B infection when you have had hepatitis B in the past (a liver infection). 
- ponovitev (reaktivacija) okužbe s hepatitisom B, če ste imeli hepatitis B v preteklosti (okužba jeter).
The median duration of the neutropenic and thrombocytopenic episodes usually ranged from 2 to 3 weeks, and from 3 to 4 weeks, respectively. 
Mediano trajanje nevtropeničnih oziroma trombocitopeničnih epizod je bilo navadno 2-3 tedne oziroma 3-4 tedne.
In addition, children and adolescents have been treated in two phase I studies (in patients with CML or Ph+ acute leukaemia) and one phase II study. 
Poleg tega so zdravili otroke v dveh študijah prve faze (pri bolnikih s KML ali Ph+ akutno levkemijo) in eni študiji druge faze.
21 patients were treated with imatinib 400 mg daily, while the other 3 patients received lower doses. 
21 bolnikov je prejemalo zdravilo Imatinib Actavis v odmerku 400 mg na dan, drugi 3 bolniki pa so prejemali manjše odmerke.
Reykjavíkurvegur 76-78 IS-220 Hafnarfjörður Iceland 
Reykjavíkurvegur 76-78 IS-220 Hafnarfjörður Islandija
A further 6 DFSP patients treated with imatinib were reported in 5 published case reports, their ages ranging from 18 months to 49 years. 
Nadaljnjih 6 bolnikov z DFSP, zdravljenih z zdravilom Imatinib Actavis, so opisali v 5 publikacijah opisov primera, njihova starost se je gibala med 18 meseci in 49 leti.
At the time of analysis, the treatment duration was a median of 47 months (24 days - 60 months). 
V času analize je bila mediana trajanja zdravljenja 47 mesecev (24 dni - 60 mesecev).
In clinical trials in CML, drug discontinuation for drug-related adverse reactions was observed in 2.4% of newly diagnosed patients, 4% of patients in late chronic phase after failure of interferon therapy, 4% of patients in accelerated phase after failure of interferon therapy and 5% of blast crisis patients after failure of interferon therapy. 
V kliničnih preskušanjih pri KML so prekinitev dajanja zdravila zaradi neželenih reakcij, povezanih z zdravilom, zabeležili pri 2,4 % na novo diagnosticiranih bolnikov, 4 % bolnikov v pozni kronični fazi po neuspelem zdravljenju z interferonom, 4 % bolnikov v pospešeni fazi po neuspelem zdravljenju z interferonom in 5 % bolnikov v blastni krizi po neuspelem zdravljenju z interferonom.
Patients will be carefully checked by their doctor for signs of this infection before treatment is started. 
Pred začetkom zdravljenja bo zdravnik skrbno pregledal bolnike glede znakov te okužbe.
It is important to cover sunexposed areas of skin and use sunscreen with high sun protection factor (SPF). 
Pomembno je, da pokrijete predele kože, ki so izpostavljeni soncu, in uporabljate zaščitno kremo z visokim zaščitnim faktorjem.
Talk to your doctor before taking Imatinib Actavis: - if you have or have ever had a liver, kidney or heart problem. 
Pred začetkom jemanja zdravila Imatinib Actavis se posvetujte s svojim zdravnikom: - če imate ali ste kdaj imeli težave z jetri, ledvicami ali srcem.
No specific dose recommendation is necessary in older people. 
Pri starejših bolnikih niso potrebna posebna priporočila glede odmerjanja.
95 (37%) had received prior chemotherapy for treatment of either accelerated phase or blast crisis (“pretreated patients”) whereas 165 (63%) had not (“untreated patients”). 
95 bolnikov (37 %) je imelo predhodno kemoterapijo za zdravljenje bodisi pospešene faze bodisi blastne krize (»predhodno zdravljeni bolniki«), medtem ko 165 bolnikov (63 %) ni bilo predhodno zdravljenih (»nezdravljeni bolniki«).
Your doctor has prescribed Imatinib Actavis because you suffer from a serious condition. 
Zdravnik vam je predpisal zdravilo Imatinib Actavis, ker imate resno bolezen.
The overall survival is 65 months since diagnosis (range 25-234). 
Celotno preživetje je 65 mesecev od postavitve diagnoze (od 25 do 234 mesecev).
This clinical effect was associated with a higher reduction in bcrabl transcripts in the imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02). 
Ta klinični učinek je bil povezan z večjim zmanjšanjem količine transkriptov bcr-abl pri bolnikih, zdravljenih z imatinibom, kot pri skupini, zdravljeni s kemoterapijo po 2 tednih zdravljenja (p=0,02).
Liver function (transaminases, bilirubin, alkaline phosphatase) should be monitored regularly in patients receiving imatinib. 
Delovanje jeter (aminotransferaza, bilirubin, alkalna fosfataza) je treba pri bolnikih, ki dobivajo imatinib, redno spremljati.
of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). 
odmerka odstranilo iz telesa v 7 dneh z blatom (68 % odmerka) in urinom (13 % odmerka).
Return to chronic phase (RTC) Major cytogenetic response2 
vrnitev v kronično fazo (RTC) Pomemben citogenetični odziv2
* These types of reactions have been reported mainly from post-marketing experience with imatinib. 
* O teh vrstah neželenih učinkov so poročali večinoma v okviru izkušenj v obdobju trženja zdravila z zdravilom Imatinib Actavis.
This may be a sign of damage to blood vessels known as thrombotic microangiopathy (TMA). 
To so lahko znaki poškodbe krvnih žil, znani kot trombotična mikroangiopatija.
- Unusual hair loss or thinning. 
- neobičajno izpadanje ali tanjšanje las,
Consolidation therapy I, III, V 
Dan konsolidacijska terapija I, III, V
- if you are allergic to imatinib, soya, peanut or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na imatinib, sojo, arašide ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
How much Imatinib Actavis to take Use in adults 
Koliko zdravila Imatinib Actavis jemati Uporaba pri odraslih
The suspension should be administered immediately after complete disintegration of the tablet(s). 
Suspenzijo je treba zaužiti takoj, ko se tableta (tablete) popolnoma razkroji (razkrojijo).
- Blood clots in small blood vessels (thrombotic microangiopathy). 
- krvni strdki v majhnih krvnih žilah (trombotična mikroangiopatija).
Imatinib did not interfere with the biotransformation of 5-fluorouracil, but it inhibited paclitaxel metabolism as a result of competitive inhibition of CYP2C8 (Ki - 34.7 µM). 
Imatinib ni oviral biotransformacije 5-fluorouracila, je pa zaviral presnovo paklitaksela zaradi kompetitivne inhibicije CYP2C8 (Ki = 34,7 μM).
Contains lecithin (soya) (E322). 
Vsebuje sojin lecitin (E322).
If this applies to you, tell your doctor without taking Imatinib Actavis. 
Če to velja za vas, povejte zdravniku in ne jemljite zdravila Imatinib Actavis.
- Unexpected bleeding or bruising (when you have not hurt yourself). 
- nepričakovana krvavitev ali modrica (ne da bi se prej poškodovali).
Out of 9 patients with chronic phase CML and cytogenetic data available, 4 (44%) and 3 (33%) achieved a complete and partial cytogenetic response, respectively, for a rate of MCyR of 77%. 
Od 9 bolnikov s kronično fazo KML in razpoložljivimi citogenetičnimi podatki so 4 (44 %) in 3 (33 %) bolniki dosegli popolni oziroma delni citogenetični odziv pri 77-odstotni stopnji MCyR.
Table 4 Chemotherapy regimen used in combination with imatinib in study I2301 
Preglednica 4 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom v študiji I2301
In patients with hepatic dysfunction (mild, moderate or severe), peripheral blood counts and liver enzymes should be carefully monitored (see sections 4.2, 4.8 and 5.2). 
Pri bolnikih z disfunkcijo jeter (blago, zmerno ali hudo) je treba skrbno spremljati periferno krvno sliko in jetrne encime (glejte poglavja 4.2, 4.8 in 5.2).
8 to 10 g (single dose): Vomiting and gastrointestinal pain have been reported. 
Odmerki od 8 g do 10 g (enkratni odmerki): Opisovali so bruhanje in bolečine v prebavilih.
The score line is not intended for breaking the tablet. 
Zareza ni namenjena lomljenju tablet.
In children and adolescents, Imatinib Actavis can be used in different phases of the disease (chronic, accelerated phase and blast crisis). 
Pri otrocih in mladostnikih se lahko zdravilo uporablja za zdravljenje različnih faz te bolezni (kronično, pospešeno fazo in blastno krizo).
They may increase or decrease the effect of Imatinib Actavis, either leading to increased side effects or making Imatinib Actavis less effective. 
Lahko povečajo ali zmanjšajo učinek zdravila Imatinib Actavis in zato bodisi povečajo verjetnost za nastanek neželenih učinkov, bodisi zmanjšajo učinkovitost zdravila Imatinib Actavis.
- Women who might become pregnant are advised to use effective contraception during treatment. 
- Ženskam, ki bi lahko zanosile, med zdravljenjem priporočamo uporabo učinkovite kontracepcijske metode.
- Swallow the tablets whole with a large glass of water. 
- Tablete pogoltnite cele z velikim kozarcem vode.
Your doctor may prescribe a higher or lower dose depending on how you respond to treatment. 
Vaš zdravnik vam lahko zdravnik predpiše večji ali manjši odmerek, odvisno od tega, kako se odzivate na zdravljenje.
Patients with advanced stages of malignancies may have numerous confounding medical conditions that make causality of adverse reactions difficult to assess due to the variety of symptoms related to the underlying disease, its progression, and the co-administration of numerous medicinal products. 
Bolniki z napredovalimi stadiji malignih bolezni imajo lahko številna sočasna medicinska stanja, ki lahko zakrijejo in ovirajo oceno vzročnosti neželenih reakcij zaradi različnih simptomov, povezanih z osnovno boleznijo, njenim napredovanjem in sočasnim dajanjem številnih zdravil.
2 Headache was the most common in GIST patients. 
2 Glavobol je bil najpogostejši pri bolnikih z GIST.
In clinical trials, there was an increased incidence of these events in elderly patients and those with a prior history of cardiac disease. 
V kliničnih preskušanjih so bili ti učinki pogostejši pri starejših bolnikih in pri bolnikih z anamnezo bolezni srca.
There are limited data on the use of imatinib in pregnant women. 
Podatkov o uporabi imatiniba pri nosečnicah je malo.
- If you are being treated for MDS/MPD: 
- Če se zdravite zaradi MDS/MPD:
It should be noted that GIST patients may have hepatic metastases which could lead to hepatic impairment. 
Upoštevati je treba, da imajo lahko bolniki z GIST metastaze v jetrih, ki lahko povzročijo okvaro jeter.
Table 3 Chemotherapy regimen used in combination with imatinib Study ADE10 
Preglednica 3 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom Študija ADE10
- If you are being treated for DFSP: 
- Če se zdravite zaradi DFSP:
- Imatinib Actavis is not recommended during pregnancy unless clearly necessary as it may harm your baby. 
- Uporabe zdravila Imatinib Actavis v nosečnosti ne priporočamo, če to ni nujno potrebno, saj lahko škoduje vašemu otroku.
(24 h), day 4; 
(24 ur), 4. dan;
The comparison of AUC(0-24) on day 8 and day 1 at the 340 mg/m2/day dose level revealed a 1.7-fold drug accumulation after repeated once-daily dosing. 
Primerjava AUC(0-24) 8. dne in 1. dne ob odmerku 340 mg/m2 je pokazala 1,7-kratno kopičenje zdravila po ponavljajočem se odmerjanju enkrat na dan.
Imatinib Actavis inhibits the growth of these cells in a certain subtype of these diseases. 
Zdravilo Imatinib Actavis zavira rast teh celic pri določenih podskupinah teh bolezni.
The high rate of CHR is accompanied by the development of a complete cytogenetic response (CCyR) of 65% which is comparable to the results observed in adults. 
Ob veliki stopnji popolnega hematološkega odziva je prišlo tudi do popolnega citogenetičnega odziva (CCyR - complete cytogenetic response) v 65 %, kar je primerljivo z zabeleženimi rezultati pri odraslih.
Based on the available data, no predisposing factors (e.g. tumour size, tumour location, coagulation disorders) have been identified that place patients with GIST at a higher risk of either type of haemorrhage. 
Na podlagi razpoložljivih podatkov niso ugotovili nikakršnih predispozicijskih dejavnikov (na primer velikost tumorja, lokacija tumorja, motnje koagulacije), ki bi pri bolnikih z GIST povečali tveganje katere od teh dveh vrst krvavitev.
The 23 patients enrolled in this registry received imatinib at a median daily dose of 264 mg (range: 100 to 400 mg) for a median duration of 7.2 years (range 0.1 to 12.7 years). 
23 bolnikov, ki so bili vključeni v register, je prejemalo imatinib z mediano dnevnega odmerka 264 mg (v razponu od 100 do 400 mg) in z mediano trajanja zdravljenja 7,2 leti (v razponu od 0,1 do 12,7 leta).
Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faeces), the remainder being metabolites. 
Nespremenjeni imatinib je predstavljal 25 % odmerka (5 % v urinu, 20 % v blatu), preostanek pa so predstavljali presnovki.
In GIST patients (study B2222), 6.8% of grade 3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade 3 or 4 AST (aspartate aminotransferase) elevations were observed. 
Pri bolnikih z GIST (študija B2222) so ugotovili 6,8 % zvišanj ALT (alanin-aminotransferaza) stopnje 3 ali 4 in 4,8 % zvišanj AST (aspartat-aminotransferaza) stopnje 3 ali 4.
- If you are being treated for CML: 
- Če se zdravite zaradi KML:
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6-MP: 6-mercaptopurine; VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v. 
Ara-C: citozin arabinozid; CP: ciklofosfamid; DEX: deksametazon; MTX: metotreksat; 6-MP: 6merkaptopurin; VM26: tenipozid; VCR: vinkristin; IDA: idarubicin; i.v.
- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Nosečnost, dojenje in plodnost - Če ste noseči ali dojite, menite, da ste noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden vzamete to zdravilo.
The effect of prior gastrointestinal surgery on drug absorption has not been investigated. 
Učinka predhodne operacije prebavil na absorpcijo zdravila niso raziskali.
When salvage therapy with imatinib was administered in patients who did not respond or who responded poorly to chemotherapy, it resulted in 9 patients (81.8%) out of 11 achieving a complete haematological response. 
Ko so imatinib uporabili kot reševalno zdravljenje pri bolnikih, pri katerih ni bilo odziva ali pa je bil odziv na kemoterapijo slab, je 9 bolnikov od 11 (81,8 %) doseglo popolni hematološki odziv.
For adult patients with relapsed or refractory Ph+ALL imatinib monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs. 
Za odrasle bolnike z relapsom ali neodzivno Ph+ ALL je zdravilo Imatinib Actavis kot monoterapija v odmerku 600 mg/dan varno in učinkovito ter ga lahko prejemajo dokler ne pride do napredovanja bolezni.
NEL Same criteria as for CHR but ANC ≥ 1 x 109/L and platelets ≥ 20 x 109/L RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, 
NEL enaki kriteriji kot za CHR, a ANC ≥ 1 x 109/L in trombociti ≥ 20 x 109/L RTC < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v
Women of childbearing potential Women of childbearing potential must be advised to use effective contraception during treatment. 
Ženskam v rodni dobi je treba svetovati, naj med zdravljenjem uporabljajo učinkovito kontracepcijo.
- adult patients with Ph+ CML in blast crisis. 
- odraslih bolnikov s Ph+ KML v blastni krizi.
Tell your doctor straight away if you get any of the following: 
takoj obvestite zdravnika:
The estimated 4-year OS in cohort 5-patients was 83.6% compared to 44.8% in the historical controls. 
Ocenjen delež bolnikov s 4-letnim celokupnim preživetjem (OS - overall survival) v 5. kohorti je bil 83,6 % v primerjavi s 44,8 % pri zgodovinskih kontrolah.
What Imatinib Actavis is and what it is used for What you need to know before you take Imatinib Actavis How to take Imatinib Actavis Possible side effects 
Kaj je zdravilo Imatinib Actavis in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Imatinib Actavis Kako jemati zdravilo Imatinib Actavis
Paediatric use: There is no experience in children with CML below 2 years of age and with Ph+ALL below 1 year of age (see section 5.1). 
Pediatrična uporaba: Izkušenj pri otrocih s KML, mlajših od 2 let, in pri otrocih s Ph+ ALL, mlajših od 1 leta, ni (glejte poglavje 5.1).
- paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. 
- pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi.
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitor, ATC code: L01XE01 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), zaviralci proteinskih kinaz, oznaka ATC: L01XE01
Increased blood urea nitrogen (BUN) and creatinine were observed in several of these animals. 
Pri mnogih od teh živali sta se zvišala dušik sečnine v krvi (BUN - blood urea nitrogen) in kreatinin.
The analysis confirmed that exposure of imatinib in paediatric patients receiving 260 mg/m2 once daily (not exceeding 400 mg once daily) or 340 mg/m2 once daily (not exceeding 600 mg once daily) were similar to those in adult patients who received imatinib 400 mg or 600 mg once daily. 
Rezultati analize potrjujejo, da je pri pediatričnih bolnikih, ki prejemajo 260 mg/m2 enkrat na dan (pri čemer odmerek ne presega 400 mg na dan) ali 340 mg/m2 enkrat na dan (pri čemer odmerek ne presega 600 mg na dan) izpostavljenost imatinibu podobna kot pri odraslih bolnikih, ki prejemajo imatinib v odmerkih 400 mg oziroma 600 mg enkrat na dan.
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Actavis should not be resumed. 
primeru, da je koncentracija protiteles proti ADAMTS13 zvišana, aktivnost ADAMTS13 pa nizka, se zdravljenja z zdravilom Imatinib Actavis ne sme nadaljevati.
If you have accidentally taken too many tablets, talk to your doctor straight away. 
Če ste pomotoma vzeli preveč tablet, se nemudoma posvetujte s svojim zdravnikom.
Studies in animals have however shown reproductive toxicity (see section 5.3) and the potential risk for the foetus is unknown. 
Študije na živalih so pokazale škodljiv vpliv na sposobnost razmnoževanja (glejte poglavje 5.3), možno tveganje za plod pa ni znano.
MDS/MPD (starting dose 400 mg) 
MDS/MPD (začetni odmerek 400 mg)
In GIST the study drug was discontinued for drug-related adverse reactions in 4% of patients. 
Pri GIST so preskušano zdravilo ukinili zaradi neželenih reakcij, povezanih z zdravilom, pri 4 % bolnikov.
It is important that you do this as long as your doctor or pharmacist tells you to. 
Pomembno je, da zdravilo jemljete tako dolgo, kot vam naroči zdravnik ali farmacevt.
Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys. 
Presnova imatiniba poteka predvsem v jetrih in le 13 % imatiniba se izloča skozi ledvice.
Thyroid stimulating hormone (TSH) levels should be closely monitored in such patients. 
Pri takih bolnikih je treba skrbno spremljati vrednosti tiroideo stimulirajočega hormona (TSH).
In non-clinical studies, the fertility of male and female rats was not affected (see section 5.3). 
Predklinične študije niso pokazale vpliva na plodnost pri podganjih samcih in samicah (glejte poglavje 5.3).